As Marinus Pharmaceuticals INC (MRNS) Shares Declined, Granite Point Capital Management LP Raised Its Position

February 20, 2018 - By Henry Gaston

Investors sentiment increased to 2.8 in Q3 2017. Its up 2.26, from 0.54 in 2017Q2. It is positive, as 8 investors sold MRNS shares while 2 reduced holdings. 20 funds opened positions while 8 raised stakes. 18.97 million shares or 171.42% more from 6.99 million shares in 2017Q2 were reported. Morgan Stanley holds 280 shares or 0% of its portfolio. Moreover, Franklin has 0.01% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Perceptive Advsr Lc reported 0.33% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Orbimed Advsrs Limited, New York-based fund reported 567,600 shares. Moreover, Northern has 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 45,678 shares. Commercial Bank Of Mellon holds 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) or 21,842 shares. Susquehanna Group Limited Liability Partnership accumulated 85,618 shares or 0% of the stock. Geode Management Limited Liability Company reported 105,104 shares stake. Farallon Cap Management Limited Liability has invested 0.06% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). State Street Corp reported 40,100 shares stake. Virtu Financial Ltd has 11,296 shares. New Leaf Venture Partners Limited owns 250,000 shares or 0.68% of their US portfolio. Caxton holds 0.1% or 16,198 shares. Shanda Asset Mgmt Hldg Ltd has 0.01% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 10,000 shares. Atika Ltd accumulated 129,000 shares or 0.22% of the stock.

Since December 15, 2017, it had 0 buys, and 2 insider sales for $10.05 million activity. Bain Capital Life Sciences Investors – LLC sold $10.02 million worth of stock or 1.27 million shares.

Warren Lammert increased its stake in Marinus Pharmaceuticals Inc (MRNS) by 250.3% based on its latest 2017Q3 regulatory filing with the SEC. Granite Point Capital Management Lp bought 1.92M shares as the company’s stock declined 21.23% while stock markets rallied. The hedge fund run by Warren Lammert held 2.68 million shares of the health care company at the end of 2017Q3, valued at $15.76M, up from 766,448 at the end of the previous reported quarter. Granite Point Capital Management Lp who had been investing in Marinus Pharmaceuticals Inc for a number of months, seems to be bullish on the $240.96M market cap company. The stock decreased 4.18% or $0.26 during the last trading session, reaching $5.96. About 535,583 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has declined 74.89% since February 20, 2017 and is downtrending. It has underperformed by 91.59% the S&P500.

Granite Point Capital Management Lp, which manages about $474.72M US Long portfolio, decreased its stake in Apple Inc (NASDAQ:AAPL) by 193,200 shares to 6,800 shares, valued at $1.05 million in 2017Q3, according to the filing.

Another recent and important Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) news was published by Globenewswire.com which published an article titled: “Marinus Pharmaceuticals to Attend Upcoming Investor Conferences” on February 07, 2018.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ratings Coverage

Among 4 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marinus Pharmaceuticals had 9 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Sector Perform” rating on Tuesday, June 14 by RBC Capital Markets. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, March 8 report. Oppenheimer maintained Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) rating on Wednesday, August 5. Oppenheimer has “Outperform” rating and $21 target. The stock has “Buy” rating by Jefferies on Tuesday, June 14. The rating was initiated by RBC Capital Markets on Thursday, December 17 with “Outperform”. Jefferies maintained Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) on Wednesday, August 10 with “Buy” rating. The firm has “Outperform” rating given on Friday, October 30 by Oppenheimer. The firm earned “Buy” rating on Tuesday, November 17 by Jefferies. As per Tuesday, June 14, the company rating was downgraded by Oppenheimer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.